

# HEALTHCARE MONTHLY

APRIL 2022

*Our healthcare team architects market-defining outcomes for some of the world's most innovative medical device, life science, diagnostics, healthcare services and pharmaceutical companies*









BioTech / Pharma

Healthcare Services

Life Sciences / Diagnostics


Medical Devices

## HEADLINE TRANSACTIONS


	TARGET	ACQUIROR	ACQUISITION SYNOPSIS
Life Sciences / Diagnostics			<ul style="list-style-type: none"> <li>Avista Public Acquisition Corp II (NASDAQ: AHPA) has reached an agreement to acquire OmniAb Inc., a division of Ligand Pharmaceuticals (NASDAQ: LGND)</li> <li>OmniAb is Ligand's antibody discovery platform, providing pharmaceutical partners with access to diverse antibody repertoires and high-throughput screening technologies</li> <li>Avista Public Acquisition Corp II (NASDAQ: AHPA) is a SPAC backed by Avista Capital Partners</li> <li>Total Consideration: \$1.0 billion, consisting of \$850 million in common shares and \$150 million in earnout</li> </ul>
Healthcare Services			<ul style="list-style-type: none"> <li>Fresenius Health Partners, InterWell Health &amp; Cricket Health have agreed to merge under the InterWell Health brand</li> <li>Fresenius, a division of Fresenius SE &amp; Co. (XTRA:FRE) provides care to patients with renal disease or other chronic conditions through a network of dialysis facilities and outpatient labs</li> <li>InterWell Health provides renal healthcare services for patients with chronic kidney disease</li> <li>Cricket Health is a technology-enabled provider of integrated nephrology and dialysis care</li> <li>The resulting combined company is valued at an estimated \$2.4 billion</li> </ul>
			<ul style="list-style-type: none"> <li>OptumHealth, Inc. entered into a definitive agreement to acquire LHC Group, Inc. (NasdaqGS:LHCG)</li> <li>OptumHealth, Inc. is a division of UnitedHealth Group (NYSE:UNH) which provides health management solutions</li> <li>LHC Group specializes in the post-acute continuum of care, primarily for Medicare beneficiaries</li> <li>Total Consideration: \$5.5 billion in cash</li> <li>Implied Enterprise Value: 2.9x LTM Revenue, 23.2x LTM EBITDA</li> <li>Represents an 8.1% premium to LHC's last closing share price</li> </ul>
BioTech / Pharma			<ul style="list-style-type: none"> <li>Fresenius Kabi Aktiengesellschaft entered into an agreement to acquire a majority stake in mAbxience</li> <li>Fresenius Kabi Aktiengesellschaft, a division of Fresenius SE &amp; Co. (XTRA:FRE) develops, manufactures, and markets pharmaceuticals and medical devices, focusing on lifesaving medicines and technologies for infusion, transfusion and clinical nutrition</li> <li>mAbxience researches, develops, manufactures and globally markets biopharmaceutical products, with a focus on biosimilars in the areas of oncology, hematology, osteoporosis and pediatrics</li> <li>Total Consideration: \$544 million</li> <li>Implied Enterprise Value: 3.5x LTM Revenue</li> </ul>

# HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins\*



\*EBITDA Margins shown as the gray line.

LTM Stock Price Index



72% BioTech / Pharma    88% Health Services    86% Life Sci / Diagnostics    93% Medical Devices    113% S&P 500 Index

# SELECTED HEALTHCARE TRANSACTIONS

Target	Acquiror	BioTech / Pharma Transactions
Acacia Pharma Group plc	Eagle Pharmaceuticals, Inc.	Acacia Pharma Group is a pharmaceutical company focused on the development of new nausea treatments for surgical and cancer patients Total Consideration: \$75 million in cash and \$23 million in stock Implied Enterprise Value: 133.4x LTM Revenue
Syndesi Therapeutics SA	AbbVie Inc.	Syndesi Therapeutics develops molecules that modulate the synaptic vesicle protein SV2A in order to develop treatments for Alzheimer's Disease Total Consideration: \$130 million in cash, \$870 million in earnout
Benuvia	Pono Capital Corp (NASDAQ: PONOU)	Benuvia is a drug developer focused on pharmaceutical cannabinoids for the treatment of nausea and appetite loss The transaction implies a combined company pro-forma Enterprise Value of \$440 million

Target	Acquiror	Life Sci / Diagnostics Transactions
Avagen Pharma, Inc.	NanoHarmonics, Inc.	Avagen Pharma develops nano-pharmaceutical products to create or improve diagnostics and pharmaceuticals in healthcare applications
Frugi Biotechnology, Inc.	BigHat Biosciences, Inc.	Frugi Biotechnology develops an automated protein therapeutic design platform for producing and characterizing antibodies, offering an AI based platform that integrates machine learning techniques to enable drug developers to create antibodies and bio therapeutic designs
BioStrand BV	ImmunoPrecise Netherlands	BioStrand BV offers an AI-powered methodology for rapidly analyzing a broad range of biological data to identify patterns to drive innovations in pharmaceutical development Total Consideration: \$2.1 million in cash and \$19.4 million in stock

Target	Acquiror	Health Services Transactions
Allscripts Healthcare Solutions (Hospitals & Large Physician Practices Segment)	Constellation Software	Allscripts Healthcare Solutions (NASDAQ: MDRX) provides information technology solutions and services to healthcare organizations – the acquired segment provides services to hospitals and large physician practices. Total Consideration: \$670 million in cash and \$30 million in earnout
Urgent Care Group (Capital Alignment Partners & Harbert Management)	ICV Partners, LLC	Urgent Care Group, LLC owns and operates a network of urgent care clinics throughout the Southeast U.S., providing care and testing services to patients
INSIGHT Health Group	CompuGroup Medical Deutschland AG	INSIGHT Health Group specializes in health care data services, including data aggregation, medication information, and AI-based disease detection Total Consideration: \$69 million Implied Enterprise Value: 1.8x LTM Revenue

Target	Acquiror	Medical Device Transactions
Nextremity Solutions, Inc.	Medartis Holding AG	Nextremity Solutions, Inc. engages in the research and development of precise implants for extremity surgery Total Consideration: \$40 million in cash and \$30 million in earnout
Advant Medical Limited	UFP Technologies, Inc.	Advant Medical is a full service contract manufacturer of medical devices Total Consideration: \$21.1 million in cash
Ivenix, Inc.	Fresenius Kabi Aktiengesellschaft	Ivenix, Inc. develops intravenous infusion system solutions and management systems Total Consideration: \$240 million in cash and earnout

## Selected TM Capital Healthcare Experience



A PORTFOLIO COMPANY OF  
**HOLLAND CAPITAL**  
HAS BEEN ACQUIRED BY  
**RadNet**



HAS RECEIVED A STRATEGIC INVESTMENT FROM  
**CATHAY CAPITAL**  
凯辉基金



HAS BEEN ACQUIRED BY  
**TRAJAN**

## TM Capital's Healthcare Industry Contacts



**James McLaren**  
Managing Director  
jmclaren@tmcapital.com  
212.809.1414



**Michael Goldman**  
Managing Director  
mgoldman@tmcapital.com  
212.809.1419



**Paul Smolevitz**  
Managing Director  
psmolevitz@tmcapital.com  
212.809.1416



**John Dean**  
Principal  
jdean@tmcapital.com  
404.995.6234



**Steve Hunter**  
Managing Director, Sponsor Coverage  
shunter@tmcapital.com  
404.995.6232